259 related articles for article (PubMed ID: 35357885)
1. Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.
Hofste Op Bruinink D; Kuiper R; van Duin M; Cupedo T; van der Velden VHJ; Hoogenboezem R; van der Holt B; Beverloo HB; Valent ET; Vermeulen M; Gay F; Broijl A; Avet-Loiseau H; Munshi NC; Musto P; Moreau P; Zweegman S; van de Donk NWCJ; Sonneveld P
J Clin Oncol; 2022 Sep; 40(27):3132-3150. PubMed ID: 35357885
[TBL] [Abstract][Full Text] [Related]
2. How We Manage Newly Diagnosed Multiple Myeloma With Circulating Tumor Cells.
van de Donk NWCJ
J Clin Oncol; 2023 Mar; 41(7):1342-1349. PubMed ID: 36450104
[No Abstract] [Full Text] [Related]
3. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study.
Guan J; Ma J; Chen B
Hematology; 2023 Dec; 28(1):2254556. PubMed ID: 37732631
[TBL] [Abstract][Full Text] [Related]
4. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.
Jelinek T; Bezdekova R; Zihala D; Sevcikova T; Anilkumar Sithara A; Pospisilova L; Sevcikova S; Polackova P; Stork M; Knechtova Z; Venglar O; Kapustova V; Popkova T; Muronova L; Chyra Z; Hrdinka M; Simicek M; Garcés JJ; Puig N; Cedena MT; Jurczyszyn A; Castillo JJ; Penka M; Radocha J; Mateos MV; San-Miguel JF; Paiva B; Pour L; Rihova L; Hajek R
J Clin Oncol; 2023 Mar; 41(7):1383-1392. PubMed ID: 36315921
[TBL] [Abstract][Full Text] [Related]
5. The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells.
Papadhimitriou SI; Terpos E; Liapis K; Pavlidis D; Marinakis T; Kastritis E; Dimopoulos MA; Tsitsilonis OE; Kostopoulos IV
Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203419
[TBL] [Abstract][Full Text] [Related]
6. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome.
Todoerti K; Agnelli L; Fabris S; Lionetti M; Tuana G; Mosca L; Lombardi L; Grieco V; Bianchino G; D'Auria F; Statuto T; Mazzoccoli C; De Luca L; Petrucci MT; Morabito F; Offidani M; Di Raimondo F; Falcone A; Omede' P; Tassone P; Boccadoro M; Palumbo A; Neri A; Musto P
Clin Cancer Res; 2013 Jun; 19(12):3247-58. PubMed ID: 23599371
[TBL] [Abstract][Full Text] [Related]
8. Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma.
Lee Y; Yun J; Jeong D; Ryu S; Kwon SR; Yun H; Kim SM; Park JH; Lee DS
Leuk Lymphoma; 2022 Feb; 63(2):385-394. PubMed ID: 34592901
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and laboratory parameters of plasma cell leukemia among Indian population.
Dubey H; Goel H; Verma S; Gupta S; Tanwar K; Rahul E; Kapoor G; Vasantharaman J; Ranjan A; Tanwar P; Chopra A
Am J Blood Res; 2022; 12(6):190-195. PubMed ID: 36742277
[TBL] [Abstract][Full Text] [Related]
10. Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background.
Rojas EA; Corchete LA; Mateos MV; García-Sanz R; Misiewicz-Krzeminska I; Gutiérrez NC
Blood Cancer J; 2019 Nov; 9(12):90. PubMed ID: 31748515
[TBL] [Abstract][Full Text] [Related]
11. [Effect of Circulating Plasma Cells on the Prognosis of Patients with Multiple Myeloma].
Li F; Gao YJ; Li SS; Xi YY; Yang XW; Su YH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1771-1779. PubMed ID: 38071059
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study.
Wang H; Zhou H; Zhang Z; Geng C; Chen W
Turk J Haematol; 2020 May; 37(2):91-97. PubMed ID: 31769277
[TBL] [Abstract][Full Text] [Related]
13. Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.
Mai EK; Hielscher T; Bertsch U; Salwender HJ; Zweegman S; Raab MS; Munder M; Pantani L; Mancuso K; Brossart P; Beksac M; Blau IW; Dürig J; Besemer B; Fenk R; Reimer P; van der Holt B; Hänel M; von Metzler I; Graeven U; Müller-Tidow C; Boccadoro M; Scheid C; Dimopoulos MA; Hillengass J; Weisel KC; Cavo M; Sonneveld P; Goldschmidt H
Leukemia; 2024 Mar; 38(3):640-647. PubMed ID: 38062124
[TBL] [Abstract][Full Text] [Related]
14. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns.
Schinke C; Boyle EM; Ashby C; Wang Y; Lyzogubov V; Wardell C; Qu P; Hoering A; Deshpande S; Ryan K; Thanendrarajan S; Mohan M; Yarlagadda N; Khan M; Choudhury SR; Zangari M; van Rhee F; Davies F; Barlogie B; Morgan G; Walker BA
Blood Cancer J; 2020 Jun; 10(6):70. PubMed ID: 32555163
[TBL] [Abstract][Full Text] [Related]
15. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L
Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
[TBL] [Abstract][Full Text] [Related]
17. Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia.
Lionetti M; Musto P; Di Martino MT; Fabris S; Agnelli L; Todoerti K; Tuana G; Mosca L; Gallo Cantafio ME; Grieco V; Bianchino G; D'Auria F; Statuto T; Mazzoccoli C; De Luca L; Petrucci MT; Offidani M; Di Raimondo F; Falcone A; Caravita T; Omede' P; Morabito F; Tassone P; Boccadoro M; Palumbo A; Neri A
Clin Cancer Res; 2013 Jun; 19(12):3130-42. PubMed ID: 23613318
[TBL] [Abstract][Full Text] [Related]
18. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols.
Usmani SZ; Nair B; Qu P; Hansen E; Zhang Q; Petty N; Waheed S; Shaughnessy JD; Alsayed Y; Heuck CJ; van Rhee F; Milner T; Hoering A; Szymonifka J; Sexton R; Sawyer J; Singh Z; Crowley J; Barlogie B
Leukemia; 2012 Nov; 26(11):2398-405. PubMed ID: 22508408
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis.
Bao L; Wang YT; Lu MQ; Chu B; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH; Liu X; Zhao X; Wang MZ; Chen Y; Hu WK
Front Endocrinol (Lausanne); 2023; 14():1157969. PubMed ID: 37181039
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.
Muccio VE; Saraci E; Gilestro M; Gattei V; Zucchetto A; Astolfi M; Ruggeri M; Marzanati E; Passera R; Palumbo A; Boccadoro M; Omedè P
Cytometry B Clin Cytom; 2016 Jan; 90(1):81-90. PubMed ID: 26287276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
